FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009299369> ?p ?o ?g. }

• W2009299369 endingPage "1283" @default.
• W2009299369 startingPage "1271" @default.
• W2009299369 abstract "After more than 50 years of treating Parkinson’s disease with l-DOPA, there are still no guidelines on setting the optimal dose for a given patient. The dopamine transporter type 1, now known as solute carrier family 6 (neurotransmitter transporter), member 3 (SLC6A3) is the most powerful determinant of dopamine neurotransmission and might therefore influence the treatment response. We recently demonstrated that methylphenidate (a dopamine transporter inhibitor) is effective in patients with Parkinson’s disease with motor and gait disorders. The objective of the present study was to determine whether genetic variants of the dopamine transporter type 1-encoding gene (SLC6A3) are associated with differences in the response to treatment of motor symptoms and gait disorders with l-DOPA and methylphenidate (with respect to the demographic, the disease and the treatment parameters and the other genes involved in the dopaminergic neurotransmission). This analysis was part of a multicentre, parallel-group, double-blind, placebo-controlled, randomized clinical trial of methylphenidate in Parkinson’s disease (Protocol ID:2008-005801-20; ClinicalTrials.gov:NCT00914095). We scored the motor Unified Parkinson's Disease Rating Scale and the Stand-Walk-Sit Test before and after a standardized acute l-DOPA challenge before randomization and then after 3 months of methylphenidate treatment. Patients were screened for variants of genes involved in dopamine metabolism: rs28363170 and rs3836790 polymorphisms in the SLC6A3 gene, rs921451 and rs3837091 in the DDC gene (encoding the aromatic L-amino acid decarboxylase involved in the synthesis of dopamine from l-DOPA), rs1799836 in the MAOB gene (coding for monoamine oxidase B) and rs4680 in the COMT gene (coding for catechol-O-methyltransferase). Investigators and patients were blinded to the genotyping data throughout the study. Eighty-one subjects were genotyped and 61 were analysed for their acute motor response to l-DOPA. The SLC6A3 variants were significantly associated with greater efficacy of l-DOPA for motor symptoms. The SLC6A3 variants were also associated with greater efficacy of methylphenidate for motor symptoms and gait disorders in the ON l-DOPA condition. The difference between motor Unified Parkinson's Disease Rating Scale scores for patients with different SLC6A3 genotypes was statistically significant in a multivariate analysis that took account of other disease-related, treatment-related and pharmacogenetic parameters. Our preliminary results suggest that variants of SLC6A3 are genetic modifiers of the treatment response to l-DOPA and methylphenidate in Parkinson’s disease. Further studies are required to assess the possible value of these genotypes for (i) guiding l-DOPA dose adaptations over the long term; and (ii) establishing the risk/benefit balance associated with methylphenidate treatment for gait disorders. Responses to L-dopa vary within and between individuals. Moreau et al. reveal that polymorphisms in the dopamine transporter gene (SLC6A3) influence the response to L-dopa and to the dopamine transporter inhibitor methylphenidate. This may help physicians to optimise L-dopa dose and to assess the risk/benefit balance for treatment with methylphenidate." @default.
• W2009299369 created "2016-06-24" @default.
• W2009299369 creator A5000345996 @default.
• W2009299369 creator A5004608080 @default.
• W2009299369 creator A5005205127 @default.
• W2009299369 creator A5010835736 @default.
• W2009299369 creator A5011954252 @default.
• W2009299369 creator A5013990412 @default.
• W2009299369 creator A5017605946 @default.
• W2009299369 creator A5019201328 @default.
• W2009299369 creator A5019351400 @default.
• W2009299369 creator A5025766736 @default.
• W2009299369 creator A5026172432 @default.
• W2009299369 creator A5040728494 @default.
• W2009299369 creator A5040964710 @default.
• W2009299369 creator A5041808791 @default.
• W2009299369 creator A5044165853 @default.
• W2009299369 creator A5045746050 @default.
• W2009299369 creator A5054027214 @default.
• W2009299369 creator A5056517132 @default.
• W2009299369 creator A5056800808 @default.
• W2009299369 creator A5057665312 @default.
• W2009299369 creator A5057730370 @default.
• W2009299369 creator A5060539794 @default.
• W2009299369 creator A5063519251 @default.
• W2009299369 creator A5069402851 @default.
• W2009299369 creator A5072526784 @default.
• W2009299369 creator A5074275756 @default.
• W2009299369 creator A5074513901 @default.
• W2009299369 creator A5074861142 @default.
• W2009299369 creator A5079246880 @default.
• W2009299369 creator A5079260684 @default.
• W2009299369 creator A5079362824 @default.
• W2009299369 creator A5082957589 @default.
• W2009299369 creator A5083292715 @default.
• W2009299369 creator A5085252034 @default.
• W2009299369 creator A5089880724 @default.
• W2009299369 creator A5091322783 @default.
• W2009299369 date "2015-03-23" @default.
• W2009299369 modified "2023-10-09" @default.
• W2009299369 title "Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease" @default.
• W2009299369 cites W1533562027 @default.
• W2009299369 cites W1922248798 @default.
• W2009299369 cites W1974978981 @default.
• W2009299369 cites W1975411793 @default.
• W2009299369 cites W1976177962 @default.
• W2009299369 cites W1988900852 @default.
• W2009299369 cites W1994661693 @default.
• W2009299369 cites W1999287190 @default.
• W2009299369 cites W1999611081 @default.
• W2009299369 cites W2006104921 @default.
• W2009299369 cites W2006373408 @default.
• W2009299369 cites W2008445652 @default.
• W2009299369 cites W2011961184 @default.
• W2009299369 cites W2023120986 @default.
• W2009299369 cites W2024131851 @default.
• W2009299369 cites W2034389220 @default.
• W2009299369 cites W2034909646 @default.
• W2009299369 cites W2037557484 @default.
• W2009299369 cites W2038444868 @default.
• W2009299369 cites W2044776651 @default.
• W2009299369 cites W2050050061 @default.
• W2009299369 cites W2064073780 @default.
• W2009299369 cites W2064201889 @default.
• W2009299369 cites W2067565974 @default.
• W2009299369 cites W2074470089 @default.
• W2009299369 cites W2080766847 @default.
• W2009299369 cites W2093331618 @default.
• W2009299369 cites W2094693628 @default.
• W2009299369 cites W2095270577 @default.
• W2009299369 cites W2108092648 @default.
• W2009299369 cites W2109856309 @default.
• W2009299369 cites W2116639272 @default.
• W2009299369 cites W2132881915 @default.
• W2009299369 cites W2134365717 @default.
• W2009299369 cites W2134886133 @default.
• W2009299369 cites W2140009084 @default.
• W2009299369 cites W2142201438 @default.
• W2009299369 cites W2143515832 @default.
• W2009299369 cites W2144700821 @default.
• W2009299369 cites W2156411508 @default.
• W2009299369 cites W2159552567 @default.
• W2009299369 cites W2166609052 @default.
• W2009299369 cites W4239908405 @default.
• W2009299369 cites W4243177274 @default.
• W2009299369 cites W4255433669 @default.
• W2009299369 doi "https://doi.org/10.1093/brain/awv063" @default.
• W2009299369 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5963414" @default.
• W2009299369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25805645" @default.
• W2009299369 hasPublicationYear "2015" @default.
• W2009299369 type Work @default.
• W2009299369 sameAs 2009299369 @default.
• W2009299369 citedByCount "48" @default.
• W2009299369 countsByYear W20092993692016 @default.
• W2009299369 countsByYear W20092993692017 @default.
• W2009299369 countsByYear W20092993692018 @default.
• W2009299369 countsByYear W20092993692019 @default.
• W2009299369 countsByYear W20092993692020 @default.

• next